JP2015529234A5 - - Google Patents

Download PDF

Info

Publication number
JP2015529234A5
JP2015529234A5 JP2015532437A JP2015532437A JP2015529234A5 JP 2015529234 A5 JP2015529234 A5 JP 2015529234A5 JP 2015532437 A JP2015532437 A JP 2015532437A JP 2015532437 A JP2015532437 A JP 2015532437A JP 2015529234 A5 JP2015529234 A5 JP 2015529234A5
Authority
JP
Japan
Prior art keywords
combination
compound
regorafenib
acetylsalicylic acid
metabolite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015532437A
Other languages
English (en)
Japanese (ja)
Other versions
JP6294888B2 (ja
JP2015529234A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/069735 external-priority patent/WO2014048881A1/en
Publication of JP2015529234A publication Critical patent/JP2015529234A/ja
Publication of JP2015529234A5 publication Critical patent/JP2015529234A5/ja
Application granted granted Critical
Publication of JP6294888B2 publication Critical patent/JP6294888B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015532437A 2012-09-25 2013-09-23 癌を治療するためのレゴラフェニブおよびアセチルサリチル酸の組み合わせ Active JP6294888B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12185852 2012-09-25
EP12185852.6 2012-09-25
PCT/EP2013/069735 WO2014048881A1 (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating cancer

Publications (3)

Publication Number Publication Date
JP2015529234A JP2015529234A (ja) 2015-10-05
JP2015529234A5 true JP2015529234A5 (https=) 2016-11-10
JP6294888B2 JP6294888B2 (ja) 2018-03-14

Family

ID=46963566

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015532437A Active JP6294888B2 (ja) 2012-09-25 2013-09-23 癌を治療するためのレゴラフェニブおよびアセチルサリチル酸の組み合わせ

Country Status (29)

Country Link
US (1) US10898500B2 (https=)
EP (1) EP2900269B1 (https=)
JP (1) JP6294888B2 (https=)
KR (1) KR102210575B1 (https=)
CN (1) CN104994876A (https=)
AU (1) AU2013322854B2 (https=)
BR (1) BR112015006686B1 (https=)
CA (1) CA2885688C (https=)
CL (1) CL2015000744A1 (https=)
CY (1) CY1120939T1 (https=)
DK (1) DK2900269T3 (https=)
EA (1) EA032023B1 (https=)
ES (1) ES2687985T3 (https=)
HK (1) HK1214169A1 (https=)
HR (1) HRP20181462T1 (https=)
HU (1) HUE039878T2 (https=)
IL (1) IL237690B (https=)
LT (1) LT2900269T (https=)
MX (1) MX357035B (https=)
MY (1) MY183969A (https=)
NZ (1) NZ705860A (https=)
PH (1) PH12015500587A1 (https=)
PL (1) PL2900269T3 (https=)
PT (1) PT2900269T (https=)
RS (1) RS57875B1 (https=)
SG (2) SG11201501963RA (https=)
SI (1) SI2900269T1 (https=)
WO (1) WO2014048881A1 (https=)
ZA (1) ZA201502840B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN09346A (https=) 2012-06-13 2015-07-17 Hoffmann La Roche
KR102179599B1 (ko) 2012-09-25 2020-11-19 에프. 호프만-라 로슈 아게 이환형 유도체
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
CN105764905B (zh) 2013-11-26 2019-06-07 豪夫迈·罗氏有限公司 新的八氢-环丁二烯并[1,2-c;3,4-c’]二吡咯-2基
WO2015144609A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
CN106103446B (zh) 2014-03-26 2019-07-30 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物
CN104829523B (zh) * 2014-04-30 2017-10-31 药源药物化学(上海)有限公司 瑞戈非尼盐及其晶型、制备方法
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CA2992889A1 (en) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
CR20180057A (es) 2015-09-24 2018-04-02 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
RU2018112230A (ru) 2015-09-24 2019-10-30 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов atx
KR20180054830A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 오토탁신(atx) 억제제로서의 이환형 화합물
AU2016328365B2 (en) 2015-09-24 2020-04-23 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
WO2018002124A1 (en) * 2016-06-28 2018-01-04 Asamedic As Two-component composition
SG11201908560SA (en) 2017-03-16 2019-10-30 Hoffmann La Roche Heterocyclic compounds useful as dual atx/ca inhibitors
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
PE20200859A1 (es) * 2017-06-02 2020-08-25 Bayer Healthcare Llc Combinacion farmaceutica que comprende regonafenib y nivolumab como anticancerigeno
EP3501522A1 (en) 2017-12-22 2019-06-26 Asamedic AS Compositions comprising acetylsalicylic acid and a phosphate salt
EP3501523A1 (en) 2017-12-22 2019-06-26 Asamedic AS Two-component compositions comprising acetyl salicylic acid and a carbonate salt
KR20210156389A (ko) 2020-06-17 2021-12-27 재단법인대구경북과학기술원 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1197228A4 (en) * 1999-07-02 2004-03-10 Hisamitsu Pharmaceutical Co DRUG COMPOSITIONS FOR THE TREATMENT OF COLORECTAL CANCER
US20040121004A1 (en) 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
EA010485B1 (ru) * 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
JP2009514921A (ja) * 2005-11-10 2009-04-09 バイエル・ヘルスケア・アクチェンゲゼルシャフト 糖尿病性神経障害を処置するためのジアリールウレア
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
GB201002530D0 (en) * 2010-02-15 2010-03-31 Univ Wolverhampton The Di-aspirin derivatives
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida

Similar Documents

Publication Publication Date Title
JP2015529234A5 (https=)
JP2012255026A5 (https=)
JP2014512354A5 (https=)
JP2015511609A5 (https=)
JP2016515628A5 (https=)
JP2014512356A5 (https=)
JP2015536964A5 (https=)
JP2016534063A5 (https=)
JP2015523397A5 (https=)
JP2015536986A5 (https=)
JP2013518107A5 (https=)
JP2014512355A5 (https=)
RU2016141569A (ru) Комбинации
JP2013522326A5 (https=)
RU2015121367A (ru) Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний
IL314360A (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
JP2016528162A5 (https=)
JP2013541595A5 (https=)
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
HRP20201316T1 (hr) Novi modulatori receptora sfingozin-fosfata
JP2015038135A5 (https=)
NZ714963A (en) Compositions and methods for treating anemia
MX342062B (es) Composicion farmaceutica para administracion oral.
NZ628392A (en) Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease